Prostate Health · BPH Treatment · Evidence
Aquablation Clinical Study Results Compared to TURP
The published trials behind Aquablation — WATER, WATER II and the pooled studies — year by year, with the limits stated. For how the procedure works and who it suits, see Aquablation therapy.
The question most men ask
Is there a best surgery for an enlarged prostate?
No single one. The AUA guideline names many surgical options for BPH and ties each to prostate size, anatomy, bleeding risk and what the man wants to preserve; the right one is the one that fits those four things. This page shows what one of them, Aquablation, did in its trials, so you can weigh it.
For every option side by side, see BPH treatment options, or go straight to Rezum, UroLift, GreenLight laser or prostate artery embolization.
The trial data
Five years, measured
The International Prostate Symptom Score, 0 to 35, is what the trials followed. Every point on this chart comes from a published paper, named beside it; what we could not verify is not drawn.
Symptom score over 60 months · trial data
- PMID 39539565 — Berjaoui MB et al. WATER vs WATER II 5-year update. BJUI Compass 2024;5:1023–33.
- PMID 30734990 — Desai M et al. WATER II six-month results. BJU Int 2019;124:321–8.
- PMID 32333733 — Desai M et al. WATER II two-year results. Can J Urol 2020;27:10147–53.
- PMID 37115632 — Bhojani N et al. WATER II final five-year results. J Urol 2023;210:143–53.
- PMID 41148264 — Siqueira MHB et al. Pooled analysis of WATER, WATER II, OPEN WATER, FRANCAIS WATER and JAPAN PMS. World J Urol 2025;43:635.
- PMID 33392647 — Whiting D et al. Single-centre OPEN WATER experience, athermal haemostasis, 1-year. World J Urol 2021;39:3019–24.
- † Reference levels: PROCEPT BioRobotics.
The same numbers, as a table
| Study and group | Month | Measure | IPSS | PMID |
|---|---|---|---|---|
| WATER · Aquablation (30–80 mL, randomized) | 0 | Score | 22.9 | 39539565 |
| WATER · Aquablation | 6 | Points improved | 16.9 | 35150215 |
| WATER · Aquablation | 12 | Points improved | 15.1 | 30552937 |
| WATER · Aquablation | 24 | Points improved | 14.7 | 31028614 |
| WATER · Aquablation | 36 | Points improved | 14.4 | 32065861 |
| WATER · Aquablation | 60 | Points improved | 15.1 | 35150215 |
| WATER · Aquablation | 60 | Score | 7.0 | 39539565 |
| WATER · TURP (control arm) | 6 | Points improved | 15.1 | 35150215 |
| WATER · TURP | 12 | Points improved | 15.1 | 30552937 |
| WATER · TURP | 24 | Points improved | 14.9 | 31028614 |
| WATER · TURP | 36 | Points improved | 13.9 | 32065861 |
| WATER · TURP | 60 | Points improved | 13.2 | 35150215 |
| WATER II (80–150 mL, single-arm) | 0 | Score | 23.2 | 30734990 |
| WATER II | 3 | Score | 6.7 | 30734990 |
| WATER II | 24 | Score | 5.8 | 32333733 |
| WATER II | 24 | Points improved | 17.0 | 32333733 |
| WATER II | 60 | Score | 6.8 (baseline 22.6 in this analysis) | 37115632 |
| WATER II | 60 | Points improved | 15.9 | 37115632 |
| Five studies pooled (n=528, 20–242 mL) | 0 | Score | 21.5 | 41148264 |
| Five studies pooled | 6 | Score | 5.8 | 41148264 |
| Five studies pooled | 12 | Score | 6.6 | 41148264 |
| OPEN WATER, one UK centre (n=55) | 0 | Score | 21.7 | 33392647 |
| OPEN WATER, one UK centre | 12 | Score | 6.1 | 33392647 |
Reference levels on the chart (†): PROCEPT BioRobotics — drug therapy about 5 IPSS points of improvement, non-resective procedures about 10. Not plotted: any value we could not find stated in a paper’s abstract.
Water Study
WATER (30–80 mL): Aquablation vs TURP, randomized and double-blind
The first WATER Study (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) compared the safety and effectiveness of Aquablation therapy to the gold standard surgical treatment for enlarged prostate, transurethral resection of the prostate (TURP). A double-blind prospective, randomized trial compared both treatments for prostates measuring in the 30 to 80 milliliter (mL) range in size. The results were the following:
- Superior safety endpoints for Aquablation compared to TURP at 3 months (incontinence, erectile dysfunction, ejaculatory dysfunction, blood transfusion)
- Comparable improvements in urinary symptoms measured by International Prostate Symptom Score (IPSS) for Aquablation versus TURP
What the trials actually showed. In the WATER trial — a double-blind randomized comparison of Aquablation against TURP in prostates of 30 to 80 cc — symptom relief at six months was non-inferior to TURP: as good, rather than better. Where Aquablation did prove superior was safety, on the trial’s primary safety endpoint, and among sexually active men the rate of anejaculation was markedly lower. Those are two different claims and we keep them apart.
181 men were randomized two to one, Aquablation to TURP. The operation took about 33 minutes against 36, and the resection itself about 4 minutes against 27 (Gilling et al., J Urol 2018, PubMed). The two groups’ symptom improvements stayed close year by year: 15.1 and 15.1 points at one year, 14.7 and 14.9 at two, 14.4 and 13.9 at three.
Comparable Symptom Score (IPSS) Improvement Compared to TURP at 6 Months
At six months the symptom score had improved by 16.9 points after Aquablation and 15.1 after TURP — the trial’s non-inferiority result. At five years the figures were 15.1 and 13.2 points, not a significant difference (p = 0.2764); flow rate had improved by 125% against 89%, and men treated with Aquablation had a 51% lower risk of needing another BPH treatment (Gilling et al., Can J Urol 2022).
Greater IPSS Improvement for Aquablation vs TURP in 50 to 80 mL Prostates
In men whose prostates were 50 mL or larger, symptom scores at five years had improved 3.5 points more after Aquablation than after TURP. That is a subgroup finding, not the trial’s primary result.
Superior Side Effect Profile and Sexual Side Effect Results for Aquablation vs TURP
On the trial’s primary safety measure, events at three months were recorded in 26% of men after Aquablation and 42% after TURP (superiority, p = 0.0149). Among sexually active men, loss of ejaculation was 10% against 36% (p = 0.0003), and at five years procedure-related ejaculatory dysfunction was 7% against 25%.
Water II Study
WATER II (80–150 mL): large glands, single-arm
The WATER II Study looked at men with larger and more difficult to treat prostates in the range of 80 to 150 mL in size.
Because WATER II had no comparison group, it shows how Aquablation performed in large glands, not how it compares with TURP there.
101 men took part, with an average prostate of 107 mL. The trial’s three-month safety goal was met: 45.5% had an event on its safety scale, against a target below 65%. Symptom scores fell from 23.2 to 6.7 by three months, and flow rate rose from 8.7 to 18.8 mL/s; men stayed in hospital 1.6 days on average (same day to six days); bleeding needing intervention or transfusion was recorded in 8 men before discharge and 6 after (Desai et al., BJU Int 2019).
At two years the score was 5.8, and all but 2 of 74 men had stopped their alpha-blockers and all but 4 of 32 their 5-alpha-reductase inhibitors (Desai et al., Can J Urol 2020). At five years the score was 6.8, flow rate had risen from 8.6 to 17.1 mL/s, 96.3% of men had not needed a second BPH procedure, and results did not differ between glands above and below 100 mL (Bhojani et al., J Urol 2023).
Beyond the two trials
Pooled and real-world results
A 2025 analysis pooled five prospective studies — WATER, WATER II, OPEN WATER, FRANCAIS WATER and a Japanese post-market study — covering 528 men with prostates from 20 to 242 mL (average 71.7). Symptom scores fell from 21.5 to 5.8 at six months and were 6.6 at a year; flow rate rose from 8.1 to 20.5 mL/s (Siqueira et al., World J Urol 2025).
One UK centre that controlled bleeding without heat reported 55 men whose scores fell from 21.7 to 6.1 at a year, with no significant change in erectile or ejaculatory function scores (Whiting et al., World J Urol 2021).
These are prospective studies, mostly supported by the manufacturer, and apart from WATER none is randomized.
The limits
Reading the numbers honestly
A non-inferiority trial asks whether a new treatment is not meaningfully worse than the standard; WATER answered yes for symptom relief. A superiority result says it is better; WATER showed that only for its safety measure.
The AUA guideline calls Aquablation’s sexual-function advantage theoretical: heat is not used to remove tissue, the reason may be the reduced removal near the verumontanum, and cautery used afterward to control bleeding may give some of it back.
The 50–80 mL advantage is a subgroup finding. Subgroups are where trials generate questions, not where they settle them.
PROCEPT BioRobotics recognizes the importance of strong clinical data to support the use of Aquablation therapy with the AquaBeam system for the treatment of benign prostatic hyperplasia (BPH). These studies were largely supported by the company, and the papers disclose their authors’ financial relationships with it; we say so because it is part of reading them.
These are published trial results, not this practice’s own figures. Individual results vary.
Common questions
Frequently Asked Questions
What is the IPSS?
The International Prostate Symptom Score: seven questions about urinary symptoms, each scored 0 to 5, for a total of 0 to 35. A score of 0–7 is usually read as mild, 8–19 as moderate and 20–35 as severe. Lower is better.
What does “non-inferior” mean?
That the trial was designed to show Aquablation was not meaningfully worse than TURP on symptom relief — and it showed that. It is not the same as showing it was better. WATER did show Aquablation was superior on its primary safety measure, which is a different question.
Why is TURP only in the “points improved” view of the chart?
Because the abstracts we verified report TURP’s results as change from baseline, not as absolute scores. We plot only values a paper states; we do not derive numbers or trace them off a manufacturer’s chart.
Are these your own results?
No. They are published trial results. We do not publish our own figures without a denominator — the number of men treated — to measure them against.
To request your consultation, please call (305) 672-4222 or contact us online today!
Contact Us
We’re here to help. Schedule your visit or ask a question today.
No question is too small — and nothing you share here surprises us. Reach out however feels easiest.
- Call(305) 672-4222
- Visit12411 Biscayne Boulevard
North Miami, FL 33181 - HoursMonday–Friday, 9:00 am – 5:00 pm
Your message goes to Dr. Robbins’ own team — you’ll hear back within one business day.
Get More Information
Need us sooner? Call (305) 672-4222.
We’re Here When You Need Us
Our Office
Visit us in North Miami, or call to book your appointment.
North Miami
- Address12411 Biscayne Boulevard
North Miami, FL 33181 - Phone(305) 672-4222
- Fax(305) 944-3624
| Monday – Friday | 9:00 am – 5:00 pm |
| Saturday – Sunday | Closed |
Care Path 01 · Enlarged prostate
In This Section
-
Prostate Health
-
Enlarged Prostate (BPH)
Start here: what the prostate does, what BPH is, and how it causes symptoms in the aging male.
-
Symptoms of BPH
Waking up at night, frequency, urgency, hesitancy and urinary retention — the symptoms, explained.
-
BPH Treatment Options
The full range of minimally invasive BPH treatments offered at our clinic, side by side.
-
Rezum for BPH
Minimally invasive water-vapor treatment of the enlarged prostate, with fewer sexual side effects.
-
UroLift for BPH
A minimally invasive, office-based outpatient procedure — an alternative to invasive surgery.
-
GreenLight Laser Surgery
GreenLight laser surgery for the enlarged prostate.
-
Aquablation Therapy
Robotic waterjet therapy for BPH with the AquaBeam system.
-
Prostate Artery Embolization
A catheter-based procedure that shrinks the prostate by reducing its blood supply — what it is, who might consider it, and our honest assessment of where it fits.
-
Tratamiento Para la Prostata Agrandada
Associations
Proud Members Of